These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23760596)

  • 21. Insulin and the brain.
    Derakhshan F; Toth C
    Curr Diabetes Rev; 2013 Mar; 9(2):102-16. PubMed ID: 23231032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.
    Kamei N; Shingaki T; Kanayama Y; Tanaka M; Zochi R; Hasegawa K; Watanabe Y; Takeda-Morishita M
    Mol Pharm; 2016 Mar; 13(3):1004-11. PubMed ID: 26795701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.
    Ved PM; Kim K
    Int J Pharm; 2011 Jun; 411(1-2):1-9. PubMed ID: 21356294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes and clinical implications of intranasal insulin administration to the central nervous system.
    Santiago JCP; Hallschmid M
    Exp Neurol; 2019 Jul; 317():180-190. PubMed ID: 30885653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice.
    Serralheiro A; Alves G; Fortuna A; Falcão A
    Int J Pharm; 2015 Jul; 490(1-2):39-46. PubMed ID: 25979854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal Neuropeptide Administration To Target the Human Brain in Health and Disease.
    Spetter MS; Hallschmid M
    Mol Pharm; 2015 Aug; 12(8):2767-80. PubMed ID: 25880274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition.
    Salameh TS; Bullock KM; Hujoel IA; Niehoff ML; Wolden-Hanson T; Kim J; Morley JE; Farr SA; Banks WA
    J Alzheimers Dis; 2015; 47(3):715-28. PubMed ID: 26401706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits.
    Yu H; Kim K
    Int J Pharm; 2009 Aug; 378(1-2):73-9. PubMed ID: 19501141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
    Hanson LR; Frey WH
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal insulin reduces olfactory sensitivity in normosmic humans.
    Brünner YF; Benedict C; Freiherr J
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1626-30. PubMed ID: 23928664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium.
    Shpakov AO; Zorina II; Derkach KV
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.
    Hanson LR; Frey WH
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):81-6. PubMed ID: 18040829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
    Freiherr J; Hallschmid M; Frey WH; Brünner YF; Chapman CD; Hölscher C; Craft S; De Felice FG; Benedict C
    CNS Drugs; 2013 Jul; 27(7):505-14. PubMed ID: 23719722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
    Kamei N; Takeda-Morishita M
    J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin.
    Reger MA; Craft S
    Drugs Today (Barc); 2006 Nov; 42(11):729-39. PubMed ID: 17171192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal insulin to improve memory function in humans.
    Benedict C; Hallschmid M; Schultes B; Born J; Kern W
    Neuroendocrinology; 2007; 86(2):136-42. PubMed ID: 17643054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.
    Benedict C; Frey WH; Schiöth HB; Schultes B; Born J; Hallschmid M
    Exp Gerontol; 2011; 46(2-3):112-5. PubMed ID: 20849944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal insulin: from nose to brain.
    Henkin RI
    Nutrition; 2010 Jun; 26(6):624-33. PubMed ID: 20022470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain targeting by intranasal drug delivery (INDD): a combined effect of trans-neural and para-neuronal pathway.
    Mustafa G; Alrohaimi AH; Bhatnagar A; Baboota S; Ali J; Ahuja A
    Drug Deliv; 2016; 23(3):933-9. PubMed ID: 24959938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain insulin signaling and Alzheimer's disease: current evidence and future directions.
    Schiöth HB; Craft S; Brooks SJ; Frey WH; Benedict C
    Mol Neurobiol; 2012 Aug; 46(1):4-10. PubMed ID: 22205300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.